Omar Khalik Siddiqi, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Zambia | 22 | 2024 | 273 | 2.010 |
Why?
|
Amyloid Neuropathies, Familial | 6 | 2022 | 180 | 1.920 |
Why?
|
Amyloidosis | 7 | 2022 | 876 | 1.770 |
Why?
|
Tuberculosis, Meningeal | 4 | 2021 | 49 | 1.680 |
Why?
|
Central Nervous System Infections | 2 | 2023 | 61 | 1.270 |
Why?
|
Diflunisal | 3 | 2022 | 7 | 1.020 |
Why?
|
Cardiomyopathies | 5 | 2022 | 2057 | 0.970 |
Why?
|
Neurology | 5 | 2023 | 785 | 0.870 |
Why?
|
Spinal Puncture | 3 | 2023 | 284 | 0.770 |
Why?
|
Prealbumin | 6 | 2022 | 259 | 0.760 |
Why?
|
Epoxide Hydrolases | 1 | 2021 | 122 | 0.730 |
Why?
|
Nervous System Diseases | 4 | 2019 | 1660 | 0.720 |
Why?
|
AIDS Dementia Complex | 3 | 2022 | 154 | 0.710 |
Why?
|
Seizures | 9 | 2024 | 2996 | 0.710 |
Why?
|
Paraparesis, Spastic | 1 | 2020 | 8 | 0.700 |
Why?
|
Amyloid | 3 | 2022 | 849 | 0.570 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 616 | 0.560 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2017 | 61 | 0.560 |
Why?
|
HIV Infections | 14 | 2024 | 17542 | 0.550 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 615 | 0.540 |
Why?
|
Immunoassay | 1 | 2019 | 744 | 0.510 |
Why?
|
Lipopolysaccharides | 2 | 2023 | 2217 | 0.500 |
Why?
|
Outpatients | 2 | 2021 | 1600 | 0.470 |
Why?
|
Herpesviridae | 1 | 2014 | 104 | 0.430 |
Why?
|
Treatment Refusal | 1 | 2015 | 433 | 0.390 |
Why?
|
Brain Waves | 1 | 2015 | 416 | 0.360 |
Why?
|
Program Development | 1 | 2017 | 1298 | 0.350 |
Why?
|
Health Resources | 1 | 2017 | 948 | 0.350 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2014 | 663 | 0.350 |
Why?
|
Ambulatory Care | 1 | 2021 | 2780 | 0.340 |
Why?
|
Coronary Restenosis | 1 | 2012 | 396 | 0.340 |
Why?
|
Coronary Thrombosis | 1 | 2012 | 440 | 0.330 |
Why?
|
Health Literacy | 1 | 2015 | 466 | 0.330 |
Why?
|
DNA, Viral | 3 | 2023 | 2201 | 0.300 |
Why?
|
Virus Diseases | 1 | 2014 | 722 | 0.290 |
Why?
|
Genotype | 2 | 2021 | 13035 | 0.290 |
Why?
|
Disease Management | 1 | 2017 | 2531 | 0.270 |
Why?
|
JC Virus | 2 | 2019 | 87 | 0.270 |
Why?
|
Drug-Eluting Stents | 1 | 2012 | 681 | 0.260 |
Why?
|
Attitude to Health | 1 | 2015 | 2023 | 0.260 |
Why?
|
Bacterial Infections | 1 | 2014 | 1390 | 0.250 |
Why?
|
Intensive Care Units | 1 | 2017 | 3797 | 0.230 |
Why?
|
Anticonvulsants | 4 | 2024 | 1921 | 0.210 |
Why?
|
Amyloidosis, Familial | 1 | 2022 | 16 | 0.200 |
Why?
|
Humans | 50 | 2024 | 767040 | 0.200 |
Why?
|
Meningitis, Cryptococcal | 1 | 2022 | 65 | 0.200 |
Why?
|
Anti-HIV Agents | 4 | 2024 | 4567 | 0.190 |
Why?
|
Epilepsy, Generalized | 1 | 2024 | 181 | 0.190 |
Why?
|
Communicable Diseases | 1 | 2010 | 872 | 0.190 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2010 | 2204 | 0.180 |
Why?
|
Meningitis | 1 | 2022 | 219 | 0.180 |
Why?
|
Manihot | 1 | 2020 | 4 | 0.180 |
Why?
|
Thiocyanates | 1 | 2020 | 70 | 0.170 |
Why?
|
DNA | 1 | 2014 | 7210 | 0.170 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2020 | 61 | 0.170 |
Why?
|
Protein Deficiency | 1 | 2020 | 57 | 0.170 |
Why?
|
Rain | 1 | 2020 | 60 | 0.170 |
Why?
|
Heart Block | 1 | 2021 | 391 | 0.170 |
Why?
|
Cyanides | 1 | 2020 | 82 | 0.170 |
Why?
|
Carbamazepine | 1 | 2020 | 224 | 0.170 |
Why?
|
Henipavirus Infections | 1 | 2019 | 7 | 0.170 |
Why?
|
Reagent Strips | 1 | 2019 | 40 | 0.160 |
Why?
|
Adult | 20 | 2023 | 223317 | 0.160 |
Why?
|
Drugs, Essential | 1 | 2019 | 71 | 0.160 |
Why?
|
Defibrillators | 1 | 2019 | 39 | 0.160 |
Why?
|
Central Nervous System | 2 | 2023 | 1345 | 0.160 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 2018 | 52 | 0.150 |
Why?
|
Heart Failure | 2 | 2019 | 11877 | 0.150 |
Why?
|
Diphosphates | 1 | 2018 | 89 | 0.150 |
Why?
|
Ambulatory Care Facilities | 2 | 2021 | 939 | 0.150 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2019 | 133 | 0.150 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1079 | 0.150 |
Why?
|
Stroke Volume | 3 | 2022 | 5618 | 0.140 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2021 | 881 | 0.140 |
Why?
|
Internship and Residency | 2 | 2018 | 5947 | 0.140 |
Why?
|
Troponin I | 1 | 2022 | 659 | 0.140 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2019 | 263 | 0.140 |
Why?
|
Melphalan | 1 | 2019 | 421 | 0.140 |
Why?
|
Developing Countries | 1 | 2010 | 2911 | 0.140 |
Why?
|
CD4 Lymphocyte Count | 3 | 2024 | 2586 | 0.140 |
Why?
|
Muscle Weakness | 1 | 2020 | 412 | 0.140 |
Why?
|
Universities | 1 | 2022 | 1004 | 0.130 |
Why?
|
Hospitals | 1 | 2010 | 3883 | 0.130 |
Why?
|
Heart Conduction System | 1 | 2021 | 1008 | 0.130 |
Why?
|
Mycobacterium tuberculosis | 2 | 2019 | 1911 | 0.130 |
Why?
|
Male | 24 | 2022 | 364203 | 0.130 |
Why?
|
Abdominal Fat | 1 | 2017 | 217 | 0.120 |
Why?
|
Young Adult | 7 | 2021 | 59980 | 0.120 |
Why?
|
Recurrence | 3 | 2018 | 8504 | 0.120 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2019 | 614 | 0.120 |
Why?
|
Age Factors | 3 | 2021 | 18401 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 849 | 0.120 |
Why?
|
RNA, Small Interfering | 2 | 2021 | 3427 | 0.120 |
Why?
|
Female | 24 | 2022 | 396660 | 0.120 |
Why?
|
Cryptococcus | 1 | 2014 | 28 | 0.110 |
Why?
|
Prevalence | 3 | 2021 | 15851 | 0.110 |
Why?
|
Fellowships and Scholarships | 1 | 2023 | 1135 | 0.110 |
Why?
|
Rural Population | 2 | 2022 | 2321 | 0.110 |
Why?
|
Seasons | 1 | 2020 | 1523 | 0.110 |
Why?
|
Neisseria meningitidis | 1 | 2014 | 111 | 0.110 |
Why?
|
Toxoplasmosis | 1 | 2014 | 94 | 0.110 |
Why?
|
DNA, Protozoan | 1 | 2014 | 227 | 0.110 |
Why?
|
Cryptococcosis | 1 | 2014 | 99 | 0.110 |
Why?
|
World Health Organization | 1 | 2019 | 1327 | 0.110 |
Why?
|
Urban Population | 1 | 2021 | 2044 | 0.110 |
Why?
|
DNA, Fungal | 1 | 2014 | 275 | 0.100 |
Why?
|
Toxoplasma | 1 | 2014 | 159 | 0.100 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15424 | 0.100 |
Why?
|
Africa South of the Sahara | 1 | 2015 | 751 | 0.100 |
Why?
|
Ventricular Function, Left | 2 | 2022 | 3934 | 0.100 |
Why?
|
Breast Feeding | 1 | 2020 | 1362 | 0.090 |
Why?
|
Retrospective Studies | 9 | 2023 | 81659 | 0.090 |
Why?
|
Genetic Markers | 1 | 2017 | 2602 | 0.090 |
Why?
|
Epilepsy | 2 | 2020 | 3317 | 0.090 |
Why?
|
Mutation | 3 | 2021 | 30211 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1761 | 0.090 |
Why?
|
Middle Aged | 14 | 2022 | 223233 | 0.090 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2726 | 0.090 |
Why?
|
Adolescent | 6 | 2021 | 89046 | 0.080 |
Why?
|
Brain | 2 | 2022 | 27163 | 0.080 |
Why?
|
Neoplasms | 1 | 2018 | 22350 | 0.080 |
Why?
|
DNA, Bacterial | 1 | 2014 | 1477 | 0.080 |
Why?
|
Streptococcus pneumoniae | 1 | 2014 | 764 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2015 | 2428 | 0.070 |
Why?
|
Glucose | 1 | 2019 | 4341 | 0.070 |
Why?
|
Survival Rate | 1 | 2021 | 12823 | 0.070 |
Why?
|
Prospective Studies | 4 | 2021 | 54886 | 0.070 |
Why?
|
Spinal Cord Diseases | 1 | 2010 | 291 | 0.070 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2011 | 519 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3591 | 0.070 |
Why?
|
Aptamers, Nucleotide | 1 | 2007 | 163 | 0.070 |
Why?
|
Child | 6 | 2024 | 80771 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10622 | 0.060 |
Why?
|
Echocardiography | 1 | 2018 | 5042 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20169 | 0.060 |
Why?
|
Inpatients | 2 | 2023 | 2563 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2023 | 65295 | 0.060 |
Why?
|
Risk Factors | 5 | 2024 | 74886 | 0.060 |
Why?
|
Ultrasonography, Interventional | 1 | 2012 | 1523 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14672 | 0.060 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2010 | 716 | 0.060 |
Why?
|
Heart Defects, Congenital | 2 | 2011 | 4713 | 0.050 |
Why?
|
Phenotype | 2 | 2021 | 16718 | 0.050 |
Why?
|
Brain Damage, Chronic | 1 | 2024 | 265 | 0.050 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 1478 | 0.050 |
Why?
|
Lead Poisoning | 1 | 2005 | 323 | 0.050 |
Why?
|
Immunoglobulin Light Chains | 1 | 2023 | 289 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2019 | 59548 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 16036 | 0.050 |
Why?
|
Blood Platelets | 1 | 2012 | 2464 | 0.050 |
Why?
|
Neuropsychological Tests | 1 | 2015 | 7121 | 0.050 |
Why?
|
Diet | 1 | 2020 | 8089 | 0.050 |
Why?
|
beta 2-Microglobulin | 1 | 2022 | 330 | 0.050 |
Why?
|
Neurodegenerative Diseases | 1 | 2010 | 1089 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2012 | 2764 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3968 | 0.040 |
Why?
|
Proline | 1 | 2022 | 454 | 0.040 |
Why?
|
Benzoxazoles | 1 | 2021 | 92 | 0.040 |
Why?
|
Glasgow Coma Scale | 1 | 2021 | 574 | 0.040 |
Why?
|
Viral Load | 2 | 2020 | 3385 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 18063 | 0.040 |
Why?
|
Stroke | 1 | 2021 | 9746 | 0.040 |
Why?
|
Tomography, Optical Coherence | 1 | 2012 | 2954 | 0.040 |
Why?
|
Electroencephalography | 1 | 2015 | 6282 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 891 | 0.040 |
Why?
|
Warfarin | 1 | 2007 | 1493 | 0.040 |
Why?
|
Incidence | 2 | 2018 | 21526 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15925 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2017 | 39317 | 0.040 |
Why?
|
Oligonucleotides | 1 | 2021 | 561 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 404 | 0.040 |
Why?
|
Area Under Curve | 1 | 2021 | 1639 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2007 | 2055 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 7059 | 0.040 |
Why?
|
Prognosis | 1 | 2018 | 29963 | 0.040 |
Why?
|
Aged | 5 | 2019 | 171319 | 0.030 |
Why?
|
International Cooperation | 1 | 2022 | 1434 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1419 | 0.030 |
Why?
|
Drug Resistance, Viral | 1 | 2020 | 868 | 0.030 |
Why?
|
Comorbidity | 1 | 2010 | 10582 | 0.030 |
Why?
|
Clinical Competence | 2 | 2023 | 4859 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 682 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2024 | 22254 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 655 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3618 | 0.030 |
Why?
|
Head | 1 | 2019 | 926 | 0.030 |
Why?
|
Cohort Studies | 3 | 2024 | 41718 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3207 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2017 | 6310 | 0.030 |
Why?
|
Time Factors | 2 | 2012 | 40154 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2014 | 26325 | 0.030 |
Why?
|
Amyloid beta-Peptides | 1 | 2005 | 3886 | 0.020 |
Why?
|
HIV | 1 | 2019 | 1591 | 0.020 |
Why?
|
Anticoagulants | 1 | 2007 | 4854 | 0.020 |
Why?
|
Leukocytes | 1 | 2019 | 2034 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2020 | 1787 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1902 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2681 | 0.020 |
Why?
|
Curriculum | 1 | 2023 | 3786 | 0.020 |
Why?
|
Hospitalization | 1 | 2009 | 10815 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12536 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 42606 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12069 | 0.020 |
Why?
|
Eye Hemorrhage | 1 | 2007 | 19 | 0.020 |
Why?
|
Parturition | 1 | 2011 | 454 | 0.020 |
Why?
|
Hospital Charges | 1 | 2009 | 345 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36582 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2019 | 4405 | 0.020 |
Why?
|
Anilino Naphthalenesulfonates | 1 | 2005 | 16 | 0.020 |
Why?
|
Barium | 1 | 2005 | 62 | 0.020 |
Why?
|
Heart | 1 | 2019 | 4429 | 0.020 |
Why?
|
United States | 3 | 2023 | 72971 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2191 | 0.020 |
Why?
|
Vitreous Body | 1 | 2007 | 401 | 0.020 |
Why?
|
Rats, Long-Evans | 1 | 2005 | 380 | 0.010 |
Why?
|
Injections | 1 | 2007 | 839 | 0.010 |
Why?
|
Choroidal Neovascularization | 1 | 2007 | 364 | 0.010 |
Why?
|
Mercury | 1 | 2005 | 289 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3414 | 0.010 |
Why?
|
Patient Admission | 1 | 2009 | 1364 | 0.010 |
Why?
|
Infant | 1 | 2024 | 36485 | 0.010 |
Why?
|
Zinc | 1 | 2005 | 675 | 0.010 |
Why?
|
Animals | 3 | 2021 | 168965 | 0.010 |
Why?
|
Macular Degeneration | 1 | 2007 | 1015 | 0.010 |
Why?
|
Lead | 1 | 2005 | 882 | 0.010 |
Why?
|
Environment | 1 | 2005 | 1120 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 2628 | 0.010 |
Why?
|
Sulfonamides | 1 | 2007 | 1982 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2005 | 1928 | 0.010 |
Why?
|
Pyrazoles | 1 | 2007 | 2028 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4143 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2007 | 3511 | 0.010 |
Why?
|
Aspirin | 1 | 2007 | 3135 | 0.010 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2005 | 3610 | 0.010 |
Why?
|
Peptides | 1 | 2005 | 4348 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10748 | 0.010 |
Why?
|
Protein Binding | 1 | 2005 | 9327 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2005 | 12793 | 0.010 |
Why?
|
Risk Assessment | 1 | 2011 | 24299 | 0.010 |
Why?
|
Pregnancy | 1 | 2011 | 30238 | 0.010 |
Why?
|
Rats | 1 | 2005 | 23713 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 9464 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15645 | 0.000 |
Why?
|